Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniele Fanale

Showing results (61-70 of 70) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 70 results.
Therapeutic Advances in Medical Oncology|March 26, 2026
An intriguing journey into the hereditary syndromes predisposing to endometrial cancer: more than believedDaniele Fanale, Luigi Magrin, Lidia Rita Corsini, et al.
Therapeutic Advances in Medical Oncology|February 23, 2023
Prognostic role of soluble PD-1 and BTN2A1 in overweight melanoma patients treated with nivolumab or pembrolizumab: finding the missing links in the symbiotic immune-metabolic interplayLorena Incorvaia, Gaetana Rinaldi, Giuseppe Badalamenti, et al.
Oncology|November 13, 2013
Analysis of germline gene copy number variants of patients with sporadic pancreatic adenocarcinoma reveals specific variationsDaniele Fanale, Juan Lucio Iovanna, Ezequiel Luis Calvo, et al.
Frontiers in Oncology|July 8, 2024
<i>BRCA</i>-associated hereditary male cancers: can gender affect the prevalence and spectrum of germline pathogenic variants?Daniele Fanale, Lidia Rita Corsini, Chiara Brando, et al.
Critical Reviews in Oncology/Hematology|October 20, 2024
Scientific Communication and oncology - "The bridge between knowledge and patients"Antonio Galvano, Andrea Gottardo, Valerio Gristina, et al.
Critical Reviews in Oncology/Hematology|November 30, 2023
Clinical relevance of exosome-derived microRNAs in Ovarian Cancer: Looking for new tumor biological fingerprintsDaniele Fanale, Lidia Rita Corsini, Marco Bono, et al.
BMC Cancer|May 13, 2023
Low plasma PD-L1 levels, early tumor onset and absence of peritoneal carcinomatosis improve prognosis of women with advanced high-grade serous ovarian cancerDaniele Fanale, Chiara Brando, Lidia Rita Corsini, et al.
Frontiers in Oncology|September 12, 2025
<i>POLE</i>-mutated endometrial cancer: new perspectives on the horizon?Daniele Fanale, Lidia Rita Corsini, Paola Piraino, et al.
Therapeutic Advances in Medical Oncology|October 7, 2021
Not all <i>KIT</i> 557/558 codons mutations have the same prognostic influence on recurrence-free survival: breaking the exon 11 mutations in gastrointestinal stromal tumors (GISTs)Lorena Incorvaia, Giuseppe Badalamenti, Daniele Fanale, et al.
Cancer Treatment Reviews|November 8, 2023
Theranostic biomarkers and PARP-inhibitors effectiveness in patients with non-BRCA associated homologous recombination deficient tumors: Still looking through a dirty glass window?Lorena Incorvaia, Alessandro Perez, Claudia Marchetti, et al.
Pageof 7

Showing results (61-70 of 70) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 70 results.
Therapeutic Advances in Medical Oncology|March 26, 2026
An intriguing journey into the hereditary syndromes predisposing to endometrial cancer: more than believedDaniele Fanale, Luigi Magrin, Lidia Rita Corsini, et al.
Therapeutic Advances in Medical Oncology|February 23, 2023
Prognostic role of soluble PD-1 and BTN2A1 in overweight melanoma patients treated with nivolumab or pembrolizumab: finding the missing links in the symbiotic immune-metabolic interplayLorena Incorvaia, Gaetana Rinaldi, Giuseppe Badalamenti, et al.
Oncology|November 13, 2013
Analysis of germline gene copy number variants of patients with sporadic pancreatic adenocarcinoma reveals specific variationsDaniele Fanale, Juan Lucio Iovanna, Ezequiel Luis Calvo, et al.
Frontiers in Oncology|July 8, 2024
<i>BRCA</i>-associated hereditary male cancers: can gender affect the prevalence and spectrum of germline pathogenic variants?Daniele Fanale, Lidia Rita Corsini, Chiara Brando, et al.
Critical Reviews in Oncology/Hematology|October 20, 2024
Scientific Communication and oncology - "The bridge between knowledge and patients"Antonio Galvano, Andrea Gottardo, Valerio Gristina, et al.
Critical Reviews in Oncology/Hematology|November 30, 2023
Clinical relevance of exosome-derived microRNAs in Ovarian Cancer: Looking for new tumor biological fingerprintsDaniele Fanale, Lidia Rita Corsini, Marco Bono, et al.
BMC Cancer|May 13, 2023
Low plasma PD-L1 levels, early tumor onset and absence of peritoneal carcinomatosis improve prognosis of women with advanced high-grade serous ovarian cancerDaniele Fanale, Chiara Brando, Lidia Rita Corsini, et al.
Frontiers in Oncology|September 12, 2025
<i>POLE</i>-mutated endometrial cancer: new perspectives on the horizon?Daniele Fanale, Lidia Rita Corsini, Paola Piraino, et al.
Therapeutic Advances in Medical Oncology|October 7, 2021
Not all <i>KIT</i> 557/558 codons mutations have the same prognostic influence on recurrence-free survival: breaking the exon 11 mutations in gastrointestinal stromal tumors (GISTs)Lorena Incorvaia, Giuseppe Badalamenti, Daniele Fanale, et al.
Cancer Treatment Reviews|November 8, 2023
Theranostic biomarkers and PARP-inhibitors effectiveness in patients with non-BRCA associated homologous recombination deficient tumors: Still looking through a dirty glass window?Lorena Incorvaia, Alessandro Perez, Claudia Marchetti, et al.
Pageof 7